NYSE:GSK - GlaxoSmithKline Stock Price, Price Target & More

GlaxoSmithKline trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

GlaxoSmithKline announced a quarterly dividend on Thursday, April 26th. Shareholders of record on Friday, May 11th will be paid a dividend of $0.5298 per share on Thursday, July 12th. This represents a $2.12 annualized dividend and a yield of 5.17%. The ex-dividend date of this dividend is Thursday, May 10th. View GlaxoSmithKline's Dividend History.

GlaxoSmithKline plc (NYSE:GSK) announced its quarterly earnings results on Wednesday, April, 25th. The pharmaceutical company reported $0.68 earnings per share for the quarter, missing analysts' consensus estimates of $0.70 by $0.02. The pharmaceutical company earned $10.04 billion during the quarter, compared to analyst estimates of $10.26 billion. GlaxoSmithKline had a return on equity of 144.84% and a net margin of 3.50%. View GlaxoSmithKline's Earnings History.

GlaxoSmithKline is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for GlaxoSmithKline.

13 Wall Street analysts have issued 1 year price objectives for GlaxoSmithKline's stock. Their forecasts range from $35.85 to $40.00. On average, they expect GlaxoSmithKline's share price to reach $38.6167 in the next twelve months. View Analyst Ratings for GlaxoSmithKline.

GlaxoSmithKline saw a drop in short interest in May. As of May 31st, there was short interest totalling 8,497,397 shares, a drop of 27.2% from the May 15th total of 11,675,520 shares. Based on an average daily trading volume, of 2,406,543 shares, the short-interest ratio is presently 3.5 days. View GlaxoSmithKline's Current Options Chain.

Some companies that are related to GlaxoSmithKline include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), Bayer (BAYRY), Sanofi (SNY), Eli Lilly And Co (LLY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Allergan (AGN), Celgene (CELG) and Shire (SHPG).

Press coverage about GSK stock has trended positive recently, Accern Sentiment reports. The research group identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. GlaxoSmithKline earned a news sentiment score of 0.44 on Accern's scale. They also assigned news stories about the pharmaceutical company an impact score of 47.78 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

GlaxoSmithKline's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Royal Bank of Canada (0.86%), Fisher Asset Management LLC (0.54%), Federated Investors Inc. PA (0.17%), Northern Trust Corp (0.13%), Equity Investment Corp (0.13%) and Schafer Cullen Capital Management Inc. (0.08%). View Institutional Ownership Trends for GlaxoSmithKline.

GSK stock was sold by a variety of institutional investors in the last quarter, including Royal Bank of Canada, Millennium Management LLC, Federated Investors Inc. PA, SeaTown Holdings Pte. Ltd., PVG Asset Management Corp, Envestnet Asset Management Inc., SG Americas Securities LLC and Thrivent Financial for Lutherans. View Insider Buying and Selling for GlaxoSmithKline.

GSK stock was bought by a variety of institutional investors in the last quarter, including Equity Investment Corp, Schafer Cullen Capital Management Inc., Fisher Asset Management LLC, BlackRock Inc., LPL Financial LLC, CIBC World Markets Inc., Northern Trust Corp and Summit Trail Advisors LLC. View Insider Buying and Selling for GlaxoSmithKline.

Shares of GSK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of GSK stock can currently be purchased for approximately $41.03.

GlaxoSmithKline has a market capitalization of $102.33 billion and generates $38.89 billion in revenue each year. The pharmaceutical company earns $1.97 billion in net income (profit) each year or $2.88 on an earnings per share basis. GlaxoSmithKline employs 99,827 workers across the globe.

GlaxoSmithKline's mailing address is 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0, TW8 9GS. The pharmaceutical company can be reached via phone at 44-20-8047-5000 or via email at [email protected]